Table 1 Association between plasma miR-3619-5p levels and clinicopathological characteristics in patients with ESCC.

From: Low levels of tumor suppressor miR-3619 in plasma contribute to malignant outcomes and a target for nucleic acid therapy in esophageal cancer

Variable

 

Plasma miR-3619-5p

Univariatea

n

High

Low

P-value

Total

94

64

30

 

Sex

     

0.778

 Male

77

53

(83%)

24

(80%)

 

 Female

17

11

(17%)

6

(20%)

 

Age (years)

     

0.119

 < 70

54

33

(52%)

21

(70%)

 

 ≥ 70

40

31

(48%)

9

(30%)

 

Histological type

     

0.246

 Well or moderately differentiated

64

41

(64%)

23

(77%)

 

 Poorly differentiated

30

23

(36%)

7

(23%)

 

Tumor size (mm)

     

0.177

 < 50

57

42

(66%)

15

(50%)

 

 ≥ 50

37

22

(34%)

15

(50%)

 

Lymphatic invasion

     

0.184

 Absent

51

38

(59%)

13

(43%)

 

 Present

43

26

(41%)

17

(57%)

 

Venous invasion

     

0.125

 Absent

49

37

(58%)

12

(40%)

 

 Present

45

27

(42%)

18

(60%)

 

pT

     

0.025

 T1

42

34

(53%)

8

(27%)

 

 T2/3/4

52

30

(47%)

22

(73%)

 

pN

     

0.046

 N0

43

34

(53%)

9

(30%)

 

 N1/2/3

51

30

(47%)

21

(70%)

 

pStage

     

0.016

 Stage I

29

25

(39%)

4

(13%)

 

 Stage II/III/IV

65

39

(61%)

26

(87%)

 

Recurrence

     

0.022

 Absent

58

45

(70%)

13

(43%)

 

 Present

36

19

(30%)

17

(57%)

 
  1. aChi-square or Fisher’s test.
  2. Note: significant values are shown in bold.
Back to article page